NDA 017001 · Bausch
Ancobon
Flucytosine · Oral · Nucleoside Analog Antifungal
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Feb 15, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1971
Nov 26, 1971
Approved uses
1
Original approval plus efficacy supplements
Registered trials
46
7 Phase 3, 3 recruiting
FAERS reports
1,418
1,362 serious, 491 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING Use with extreme caution in patients with impaired renal function. Close monitoring of hematologic, renal and hepatic status of all patients is essential. These instructions should be thoroughly reviewed before administration of ANCOBON.
What it is approved for
From the label in effect Feb 2, 2022.
INDICATIONS AND USAGE ANCOBON is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. ANCOBON should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to ANCOBON (see MICROBIOLOGY ).
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 26, 1971 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- ANCOBON · FLUCYTOSINE 500MG · CAPSULE, ORAL · Prescription · TE AB
- ANCOBON · FLUCYTOSINE 250MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Flucytosine" as an intervention, any sponsor and status, largest first.
- Platform Trial For Cryptococcal Meningitis (PLATFORM-CM)Pivotal-lookingRecruiting
David BoulwareAcademic, hospital or other
NCT06666322 · 2,000 participants (planned) · Start May 28, 2025 · Primary completion Apr 21, 2032
Drug: Standard of care; Oteseconazole - antifungal therapy 1 and 3 more · For: Hiv; Cryptococcal Meningitis
Sites: Kampala, Uganda; Mbarara, Uganda
- Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)Pivotal-lookingNot yet recruiting
Duke UniversityAcademic, hospital or other
NCT06525389 · 428 participants (planned) · Start Nov 2026 · Primary completion Sep 1, 2030
Drug: Liposomal Amphotericin B (LAmB); Flucytosine (5FC) and 2 more · For: Talaromycosis
Sites: Durham, North Carolina; Hanoi, Vietnam; Ho Chi Minh City, Vietnam · 5 sites in all
- The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade GliomaPivotal-lookingTerminated
Tocagen Inc.Industry
NCT02414165 · 403 participants · Start Nov 30, 2015 · Primary completion May 31, 2019
Drug: Toca 511; Toca FC and 3 more · For: Glioblastoma Multiforme; Anaplastic Astrocytoma
Sites: Phoenix, Arizona; Irvine, California; La Jolla, California · 67 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000639 · 400 participants
Drug: Itraconazole; Flucytosine and 2 more · For: Meningitis, Cryptococcal; HIV Infections
Sites: Los Angeles, California; San Francisco, California; Miami, Florida · 24 sites in all
- Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3Pivotal-lookingStatus unknown
Matinas BioPharma Nanotechnologies, Inc.Industry
NCT05541107 · 270 participants (planned) · Start Jan 2023 · Primary completion Oct 2024
Drug: MAT2203; Amphotericin B · For: Cryptococcal Meningitis
- Amphotericin B for Non-HIV Cryptococcal Meningitis PatientsPivotal-lookingStatus unknown
Huashan HospitalAcademic, hospital or other
NCT06178627 · 250 participants (planned) · Start Aug 13, 2023 · Primary completion Aug 31, 2025
Drug: Amphotericin B 0.5 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.; Amphotericin B 0.7 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks. · For: Cryptococcal Meningitis; Antifungal Agents
Sites: Shanghai, China; Nanning, China
- Three Induction Treatments on Cryptococcal MeningitisPivotal-lookingStatus unknown
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT04072640 · 120 participants (planned) · Start Jan 25, 2021 · Primary completion Jul 31, 2022
Drug: Voriconazole 200mg; amphotericin B deoxycholate (0.4-0.5mg/kg/d) and 1 more · For: Cryptococcal Meningitis; HIV/AIDS
Sites: Zhenjiang, China
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000708 · 120 participants · Primary completion Jul 1991
Drug: Flucytosine; Fluconazole and 1 more · For: Meningitis, Cryptococcal; HIV Infections
Sites: Miami, Florida; New Orleans, Louisiana; New York, New York · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective467
- off label use140
- immune reconstitution inflammatory syndrome105
- meningitis cryptococcal98
- acute kidney injury88
- renal impairment79
- condition aggravated76
- cryptococcosis66
- disseminated cryptococcosis66
- drug interaction58
- headache58
- pyrexia58
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 9 |
| 2005 | 9 |
| 2006 | 3 |
| 2007 | 12 |
| 2008 | 22 |
| 2009 | 20 |
| 2010 | 24 |
| 2011 | 12 |
| 2012 | 23 |
| 2013 | 19 |
| 2014 | 28 |
| 2015 | 30 |
| 2016 | 40 |
| 2017 | 64 |
| 2018 | 60 |
| 2019 | 89 |
| 2020 | 120 |
| 2021 | 116 |
| 2022 | 124 |
| 2023 | 127 |
| 2024 | 138 |
| 2025 | 181 |
| 2026 | 145 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.
Jarvis JN, Lawrence DS, Meya DB, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Equivalence Trial
- Candida albicans-A systematic review to inform the World Health Organization Fungal Priority Pathogens List.
Parambath S, Dao A, Kim HY, et al. · Med Mycol 2024 · Systematic Review
- Cryptococcosis-a systematic review to inform the World Health Organization Fungal Priority Pathogens List.
Dao A, Kim HY, Garnham K, et al. · Med Mycol 2024 · Systematic Review
- Flucytosine monotherapy for cryptococcosis.
Hospenthal DR, Bennett JE · Clin Infect Dis 1998 · Clinical Trial
- Treatment for HIV-associated cryptococcal meningitis.
Tenforde MW, Shapiro AE, Rouse B, et al. · Cochrane Database Syst Rev 2018 · Research Support, Non-U.S. Gov't, Systematic Review
- Cryptococcosis in Africa: What the data tell us.
Ibe C, Okoye CA, Nweze E, et al. · Med Mycol 2023 · Systematic Review
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.